(Q34464997)

2 August 2017

title

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring (English)

1 reference

2 August 2017

1 reference

Félix Gutiérrez

1

1 reference

2 August 2017

Andrés Navarro

2

1 reference

2 August 2017

Sergio Padilla

3

1 reference

2 August 2017

Rosa Antón

4

1 reference

2 August 2017

Mar Masiá

5

1 reference

2 August 2017

Joaquín Borrás

6

1 reference

2 August 2017

Alberto Martín-Hidalgo

7

1 reference

2 August 2017

language of work or name

English

0 references

publication date

19 October 2005

1 reference

Clinical Infectious Diseases

2 August 2017

published in

1 reference

2 August 2017

volume

41

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1648-1653

1 reference

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

2 August 2017

cites work

1 reference

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

21 January 2018

1 reference

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

Management of sudden psychiatric disorders related to efavirenz

21 January 2018

1 reference

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

21 January 2018

1 reference

Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine

21 January 2018

1 reference

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/497835

1 reference

2 August 2017

1 reference